RelA-induced interferon response negatively regulates proliferation

PLoS ONE

Volumn 10, Issue 10, 2015, Pages

  Kochupurakkal, Bose S ^a   Wang, Zhigang C ^a   Hua, Tony ^a   Culhane, Aedin C ^a   Rodig, Scott J ^b   Rajkovic Molek, Koraljka ^c   Lazaro, Jean Bernard ^a   Richardson, Andrea L ^a,b   Biswas, Debajit K ^a   Iglehart, J Dirk ^a,b  

^a DANA FARBER CANCER INSTITUTE   (United States)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

^c KBC RIJEKA   (Croatia)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIN DEPENDENT KINASE 4; DOXORUBICIN; GAMMA INTERFERON; INTERFERON REGULATORY FACTOR 1; INTERFERON REGULATORY FACTOR 7; PROTEIN P27; RETINOBLASTOMA PROTEIN; STAT1 PROTEIN; TRANSCRIPTION FACTOR RELA; INTERFERON; IRF1 PROTEIN, HUMAN; MICRORNA; PROTEIN P53;

ARTICLE; BREAST EPITHELIUM CELL; BREAST TUMOR; CELL CYCLE ARREST; CELL PROLIFERATION; CONTROLLED STUDY; DOWN REGULATION; DRUG SENSITIVITY; FLOW CYTOMETRY; GENE EXPRESSION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IRF1 GENE; PLASMID; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; TISSUE MICROARRAY; UPREGULATION; WESTERN BLOTTING; BREAST; CELL CYCLE CHECKPOINT; CELL LINE; CYTOLOGY; DRUG EFFECTS; EPITHELIUM CELL; FALLOPIAN TUBE; FEMALE; METABOLISM; PATHOLOGY; PHOSPHORYLATION;

BREAST; BREAST NEOPLASMS; CELL CYCLE CHECKPOINTS; CELL LINE; CELL PROLIFERATION; CYCLIN-DEPENDENT KINASE 4; DOWN-REGULATION; EPITHELIAL CELLS; FALLOPIAN TUBES; FEMALE; HUMANS; INTERFERON REGULATORY FACTOR-1; INTERFERON-GAMMA; INTERFERONS; MICRORNAS; PHOSPHORYLATION; RETINOBLASTOMA PROTEIN; TRANSCRIPTION FACTOR RELA; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84949024159     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0140243     Document Type: Article

References (100)

1. Cao Y, Karin M. NF-kappaB in mammary gland development and breast cancer. Journal of mammary gland biology and neoplasia. 2003; 8(2):215-23. PMID: 14635796.
2. Hayden MS, Ghosh S. Shared principles in NF-kappaB signaling. Cell. 2008; 132(3):344-62. doi: 10. 1016/j.cell.2008.01.020 PMID: 18267068.
3. Liu M, Ju X, Willmarth NE, Casimiro MC, Ojeifo J, Sakamaki T, et al. Nuclear factor-kappaB enhances ErbB2-induced mammary tumorigenesis and neoangiogenesis in vivo. The American journal of pathology. 2009; 174(5):1910-20. doi: 10.2353/ajpath.2009.080706 PMID: 19349372; PubMed Central PMCID: PMC2671278.
4. Cao Y, Luo JL, Karin M. IkappaB kinase alpha kinase activity is required for self-renewal of ErbB2/Her2-transformed mammary tumor-initiating cells. Proceedings of the National Academy of Sciences of the United States of America. 2007; 104(40):15852-7. doi: 10.1073/pnas.0706728104 PMID: 17890319; PubMed Central PMCID: PMC2000410.
5. Demicco EG, Kavanagh KT, Romieu-Mourez R, Wang X, Shin SR, Landesman-Bollag E, et al. RelB/p52 NF-kappaB complexes rescue an early delay in mammary gland development in transgenic mice with targeted superrepressor IkappaB-alpha expression and promote carcinogenesis of the mammary gland. Molecular and cellular biology. 2005; 25(22):10136-47. doi: 10.1128/MCB.25.22.10136-10147.2005 PMID: 16260626; PubMed Central PMCID: PMC1280249.
6. Brantley DM, Chen CL, Muraoka RS, Bushdid PB, Bradberry JL, Kittrell F, et al. Nuclear factor-kappaB (NF-kappaB) regulates proliferation and branching in mouse mammary epithelium. Molecular biology of the cell. 2001; 12(5):1445-55. PMID: 11359934; PubMed Central PMCID: PMC34596.
7. Romieu-Mourez R, Kim DW, Shin SM, Demicco EG, Landesman-Bollag E, Seldin DC, et al. Mouse mammary tumor virus c-rel transgenic mice develop mammary tumors. Molecular and cellular biology. 2003; 23(16):5738-54. PMID: 12897145; PubMed Central PMCID: PMC166341.
8. Vargo-Gogola T, Rosen JM. Modelling breast cancer: One size does not fit all. Nature reviews Cancer. 2007; 7(9):659-72. doi: 10.1038/nrc2193 PMID: 17721431.
9. Rangarajan A, Hong SJ, Gifford A, Weinberg RA. Species-and cell type-specific requirements for cellular transformation. Cancer cell. 2004; 6(2):171-83. doi: 10.1016/j.ccr.2004.07.009 PMID: 15324700.
10. Cancer Genome Atlas N. Comprehensive molecular portraits of human breast tumours. Nature. 2012; 490(7418):61-70. doi: 10.1038/nature11412 PMID: 23000897; PubMed Central PMCID: PMC3465532.
11. Biswas DK, Shi Q, Baily S, Strickland I, Ghosh S, Pardee AB, et al. NF-kappa B activation in human breast cancer specimens and its role in cell proliferation and apoptosis. Proceedings of the National Academy of Sciences of the United States of America. 2004; 101(27):10137-42. doi: 10.1073/pnas. 0403621101 PMID: 15220474; PubMed Central PMCID: PMC454178.
12. Nakshatri H, Bhat-Nakshatri P, Martin DA, Goulet RJ Jr, Sledge GW Jr. Constitutive activation of NFkappaB during progression of breast cancer to hormone-independent growth. Molecular and cellular biology. 1997; 17(7):3629-39. PMID: 9199297; PubMed Central PMCID: PMC232215.
13. Zhou Y, Eppenberger-Castori S, Marx C, Yau C, Scott GK, Eppenberger U, et al. Activation of nuclear factor-kappaB (NFkappaB) identifies a high-risk subset of hormone-dependent breast cancers. The international journal of biochemistry & cell biology. 2005; 37(5):1130-44. doi: 10.1016/j.biocel.2004. 09.006 PMID: 15743683.
14. Sovak MA, Bellas RE, Kim DW, Zanieski GJ, Rogers AE, Traish AM, et al. Aberrant nuclear factorkappaB/Rel expression and the pathogenesis of breast cancer. The Journal of clinical investigation. 1997; 100(12):2952-60. doi: 10.1172/JCI119848 PMID: 9399940; PubMed Central PMCID: PMC508506.
15. Cogswell PC, Guttridge DC, Funkhouser WK, Baldwin AS Jr. Selective activation of NF-kappa B subunits in human breast cancer: Potential roles for NF-kappa B2/p52 and for Bcl-3. Oncogene. 2000; 19 (9):1123-31. doi: 10.1038/sj.onc.1203412 PMID: 10713699.
16. Jones RL, Rojo F, A'Hern R, Villena N, Salter J, Corominas JM, et al. Nuclear NF-kappaB/p65 expression and response to neoadjuvant chemotherapy in breast cancer. Journal of clinical pathology. 2011; 64(2):130-5. doi: 10.1136/jcp.2010.082966 PMID: 21148141.
17. Singh S, Shi Q, Bailey ST, Palczewski MJ, Pardee AB, Iglehart JD, et al. Nuclear factor-kappaB activation: A molecular therapeutic target for estrogen receptor-negative and epidermal growth factor receptor family receptor-positive human breast cancer. Molecular cancer therapeutics. 2007; 6 (7):1973-82. doi: 10.1158/1535-7163.MCT-07-0063 PMID: 17620428.
18. Sheehy AM, Schlissel MS. Overexpression of RelA causes G1 arrest and apoptosis in a pro-B cell line. The Journal of biological chemistry. 1999; 274(13):8708-16. PMID: 10085110.
19. Ricca A, Biroccio A, Trisciuoglio D, Cippitelli M, Zupi G, Del Bufalo D. relA over-expression reduces tumorigenicity and activates apoptosis in human cancer cells. British journal of cancer. 2001; 85 (12):1914-21. doi: 10.1054/bjoc.2001.2174 PMID: 11747334; PubMed Central PMCID: PMC2364001.
20. Jacque E, Billot K, Authier H, Bordereaux D, Baud V. RelB inhibits cell proliferation and tumor growth through p53 transcriptional activation. Oncogene. 2013; 32(21):2661-9. doi: 10.1038/onc.2012.282 PMID: 22777360.
21. Wang J, Jacob NK, Ladner KJ, Beg A, Perko JD, Tanner SM, et al. RelA/p65 functions to maintain cellular senescence by regulating genomic stability and DNA repair. EMBO reports. 2009; 10(11):1272-8. doi: 10.1038/embor.2009.197 PMID: 19779484; PubMed Central PMCID: PMC2775178.
22. Salminen A, Kauppinen A, Kaarniranta K. Emerging role of NF-kappaB signaling in the induction of senescence-associated secretory phenotype (SASP). Cellular signalling. 2012; 24(4):835-45. doi: 10.1016/j.cellsig.2011.12.006 PMID: 22182507.
23. Chien Y, Scuoppo C, Wang X, Fang X, Balgley B, Bolden JE, et al. Control of the senescence-associated secretory phenotype by NF-kappaB promotes senescence and enhances chemosensitivity. Genes & development. 2011; 25(20):2125-36. doi: 10.1101/gad.17276711 PMID: 21979375; PubMed Central PMCID: PMC3205583.
24. Seitz CS, Lin Q, Deng H, Khavari PA. Alterations in NF-kappaB function in transgenic epithelial tissue demonstrate a growth inhibitory role for NF-kappaB. Proceedings of the National Academy of Sciences of the United States of America. 1998; 95(5):2307-12. PMID: 9482881; PubMed Central PMCID: PMC19329.
25. Zhao JJ, Gjoerup OV, Subramanian RR, Cheng Y, Chen W, Roberts TM, et al. Human mammary epithelial cell transformation through the activation of phosphatidylinositol 3-kinase. Cancer cell. 2003; 3 (5):483-95. PMID: 12781366.
26. Karst AM, Drapkin R. Primary culture and immortalization of human fallopian tube secretory epithelial cells. Nature protocols. 2012; 7(9):1755-64. doi: 10.1038/nprot.2012.097 PMID: 22936217.
27. Lamesch P, Li N, Milstein S, Fan C, Hao T, Szabo G, et al. hORFeome v3.1: A resource of human open reading frames representing over 10,000 human genes. Genomics. 2007; 89(3):307-15. doi: 10.1016/j.ygeno.2006.11.012 PMID: 17207965.
28. Kochupurakkal BS, Iglehart JD. Nourseothricin N-acetyl transferase: A positive selection marker for mammalian cells. PloS one. 2013; 8(7):e68509. doi: 10.1371/journal.pone.0068509 PMID: 23861913; PubMed Central PMCID: PMC3701686.
29. Schmidt EE, Pelz O, Buhlmann S, Kerr G, Horn T, Boutros M. GenomeRNAi: A database for cellbased and in vivo RNAi phenotypes, 2013 update. Nucleic acids research. 2013; 41(Database issue): D1021-6. doi: 10.1093/nar/gks1170 PMID: 23193271; PubMed Central PMCID: PMC3531141.
30. Utermark T, Schaffhausen BS, Roberts TM, Zhao JJ. The p110alpha isoform of phosphatidylinositol 3-kinase is essential for polyomavirus middle T antigen-mediated transformation. Journal of virology. 2007; 81(13):7069-76. doi: 10.1128/JVI.00115-07 PMID: 17442716; PubMed Central PMCID: PMC1933267.
31. Borger DR, DeCaprio JA. Targeting of p300/CREB binding protein coactivators by simian virus 40 is mediated through p53. Journal of virology. 2006; 80(9):4292-303. doi: 10.1128/JVI.80.9.4292-4303. 2006 PMID: 16611888; PubMed Central PMCID: PMC1472010.
32. Chua HL, Bhat-Nakshatri P, Clare SE, Morimiya A, Badve S, Nakshatri H. NF-kappaB represses Ecadherin expression and enhances epithelial to mesenchymal transition of mammary epithelial cells: Potential involvement of ZEB-1 and ZEB-2. Oncogene. 2007; 26(5):711-24. doi: 10.1038/sj.onc. 1209808 PMID: 16862183.
33. Broadinstitute.org website. http://www.broadinstitute.org/rnai/public/.
34. Farrell CM O'Leary NA, Harte RA, Loveland JE, Wilming LG, Wallin C, et al. Current status and new features of the Consensus Coding Sequence database. Nucleic acids research. 2014; 42(Database issue):D865-72. doi: 10.1093/nar/gkt1059 PMID: 24217909; PubMed Central PMCID: PMC3965069.
35. Boehm JS, Zhao JJ, Yao J, Kim SY, Firestein R, Dunn IF, et al. Integrative genomic approaches identify IKBKE as a breast cancer oncogene. Cell. 2007; 129(6):1065-79. doi: 10.1016/j.cell.2007.03.052 PMID: 17574021.
36. Root DE, Hacohen N, Hahn WC, Lander ES, Sabatini DM. Genome-scale loss-of-function screening with a lentiviral RNAi library. Nature methods. 2006; 3(9):715-9. doi: 10.1038/nmeth924 PMID: 16929317.
37. Dai M, Wang P, Boyd AD, Kostov G, Athey B, Jones EG, et al. Evolving gene/transcript definitions significantly alter the interpretation of GeneChip data. Nucleic acids research. 2005; 33(20):e175. doi: 10.1093/nar/gni179 PMID: 16284200; PubMed Central PMCID: PMC1283542.
38. Reich M, Liefeld T, Gould J, Lerner J, Tamayo P, Mesirov JP. GenePattern 2.0. Nature genetics. 2006; 38(5):500-1. doi: 10.1038/ng0506-500 PMID: 16642009.
39. Subramanian A, Tamayo P, Mootha VK,Mukherjee S, Ebert BL, Gillette MA, et al. Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profiles. Proceedings of the National Academy of Sciences of the United States of America. 2005; 102(43):15545-50. doi: 10.1073/pnas.0506580102 PMID: 16199517; PubMed Central PMCID: PMC1239896.
40. Saeed AI, Sharov V, White J, Li J, Liang W, Bhagabati N, et al. TM4: A free, open-source system for microarray data management and analysis. BioTechniques. 2003; 34(2):374-8. PMID: 12613259.
41. Broadinstitute.org website. http://gdac.broadinstitute.org/.
42. Yoshihara K, Shahmoradgoli M, Martinez E, Vegesna R, Kim H, Torres-Garcia W, et al. Inferring tumour purity and stromal and immune cell admixture from expression data. Nature communications. 2013; 4:2612. doi: 10.1038/ncomms3612 PMID: 24113773; PubMed Central PMCID: PMC3826632.
43. Lu X, Lu X, Wang ZC, Iglehart JD, Zhang X, Richardson AL. Predicting features of breast cancer with gene expression patterns. Breast cancer research and treatment. 2008; 108(2):191-201. doi: 10. 1007/s10549-007-9596-6 PMID: 18297396.
44. Rajkovic-Molek K, Mustac E, Hadzisejdic I, Jonjic N. The prognostic importance of nuclear factor kappaB and hypoxia-inducible factor 1alpha in relation to the breast cancer subtype and the overall survival. Applied immunohistochemistry & molecular morphology: AIMM/official publication of the Society for Applied Immunohistochemistry. 2014; 22(6):464-70. doi: 10.1097/PAI. 0b013e31829271ce PMID: 23958545.
45. Kindelberger DW, Lee Y, Miron A, Hirsch MS, Feltmate C,Medeiros F, et al. Intraepithelial carcinoma of the fimbria and pelvic serous carcinoma: Evidence for a causal relationship. The American journal of surgical pathology. 2007; 31(2):161-9. doi: 10.1097/01.pas.0000213335.40358.47 PMID: 17255760.
46. Hahn WC, Dessain SK, Brooks MW, King JE, Elenbaas B, Sabatini DM, et al. Enumeration of the simian virus 40 early region elements necessary for human cell transformation. Molecular and cellular biology. 2002; 22(7):2111-23. PMID: 11884599; PubMed Central PMCID: PMC133688.
47. Shaulian E, Zauberman A, Ginsberg D, Oren M. Identification of a minimal transforming domain of p53: Negative dominance through abrogation of sequence-specific DNA binding. Molecular and cellular biology. 1992; 12(12):5581-92. PMID: 1448088; PubMed Central PMCID: PMC360497.
48. Dontu G, Abdallah WM, Foley JM, Jackson KW, Clarke MF, Kawamura MJ, et al. In vitro propagation and transcriptional profiling of human mammary stem/progenitor cells. Genes & development. 2003; 17(10):1253-70. doi: 10.1101/gad.1061803 PMID: 12756227; PubMed Central PMCID: PMC196056.
49. Haibe-Kains B, Desmedt C, Loi S, Culhane AC, Bontempi G, Quackenbush J, et al. A three-gene model to robustly identify breast cancer molecular subtypes. Journal of the National Cancer Institute. 2012; 104(4):311-25. doi: 10.1093/jnci/djr545 PMID: 22262870; PubMed Central PMCID: PMC3283537.
50. Rubin SM. Deciphering the retinoblastoma protein phosphorylation code. Trends in biochemical sciences. 2013; 38(1):12-9. doi: 10.1016/j.tibs.2012.10.007 PMID: 23218751; PubMed Central PMCID: PMC3529988.
51. Huang B, Yang XD, Lamb A, Chen LF. Posttranslational modifications of NF-kappaB: Another layer of regulation for NF-kappaB signaling pathway. Cellular signalling. 2010; 22(9):1282-90. doi: 10.1016/j. cellsig.2010.03.017 PMID: 20363318; PubMed Central PMCID: PMC2893268.
52. Yu Q, Sicinska E, Geng Y, Ahnstrom M, Zagozdzon A, Kong Y, et al. Requirement for CDK4 kinase function in breast cancer. Cancer cell. 2006; 9(1):23-32. doi: 10.1016/j.ccr.2005.12.012 PMID: 16413469.
53. Reddy HK, Mettus RV, Rane SG, Grana X, Litvin J, Reddy EP. Cyclin-dependent kinase 4 expression is essential for neu-induced breast tumorigenesis. Cancer research. 2005; 65(22):10174-8. doi: 10. 1158/0008-5472.CAN-05-2639 PMID: 16288002.
54. Chu I, Sun J, Arnaout A, Kahn H, Hanna W, Narod S, et al. p27 phosphorylation by Src regulates inhibition of cyclin E-Cdk2. Cell. 2007; 128(2):281-94. doi: 10.1016/j.cell.2006.11.049 PMID: 17254967; PubMed Central PMCID: PMC1961623.
55. Finn RS, Crown JP, Lang I, Boer K, Bondarenko IM, Kulyk SO, et al. The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): A randomised phase 2 study. The Lancet Oncology. 2015; 16(1):25-35. doi: 10.1016/S1470-2045(14)71159-3 PMID: 25524798.
56. Dean JL, Thangavel C, McClendon AK, Reed CA, Knudsen ES. Therapeutic CDK4/6 inhibition in breast cancer: Key mechanisms of response and failure. Oncogene. 2010; 29(28):4018-32. doi: 10. 1038/onc.2010.154 PMID: 20473330.
57. Schwartz JL, Shajahan AN, Clarke R. The Role of Interferon Regulatory Factor-1 (IRF1) in Overcoming Antiestrogen Resistance in the Treatment of Breast Cancer. International journal of breast cancer. 2011; 2011:912102. doi: 10.4061/2011/912102 PMID: 22295238; PubMed Central PMCID: PMC3262563.
58. Li Q, Tang L, Roberts PC, Kraniak JM, Fridman AL, Kulaeva OI, et al. Interferon regulatory factors IRF5 and IRF7 inhibit growth and induce senescence in immortal Li-Fraumeni fibroblasts. Molecular cancer research: MCR. 2008; 6(5):770-84. doi: 10.1158/1541-7786.MCR-07-0114 PMID: 18505922; PubMed Central PMCID: PMC3842195.
59. Bailey CM, Abbott DE, Margaryan NV, Khalkhali-Ellis Z, Hendrix MJ. Interferon regulatory factor 6 promotes cell cycle arrest and is regulated by the proteasome in a cell cycle-dependent manner. Molecular and cellular biology. 2008; 28(7):2235-43. doi: 10.1128/MCB.01866-07 PMID: 18212048; PubMed Central PMCID: PMC2268429.
60. Ikushima H, Negishi H, Taniguchi T. The IRF family transcription factors at the interface of innate and adaptive immune responses. Cold Spring Harbor symposia on quantitative biology. 2013; 78:105-16. doi: 10.1101/sqb.2013.78.020321 PMID: 24092468.
61. Shultz DB, Rani MR, Fuller JD, Ransohoff RM, Stark GR. Roles of IKK-beta, IRF1, and p65 in the activation of chemokine genes by interferon-gamma. Journal of interferon & cytokine research: The official journal of the International Society for Interferon and Cytokine Research. 2009; 29(12):817-24. doi: 10.1089/jir.2009.0034 PMID: 19929594; PubMed Central PMCID: PMC2956658.
62. Armstrong MJ, Stang MT, Liu Y, Gao J, Ren B, Zuckerbraun BS, et al. Interferon Regulatory Factor 1 (IRF-1) induces p21(WAF1/CIP1) dependent cell cycle arrest and p21(WAF1/CIP1) independent modulation of survivin in cancer cells. Cancer letters. 2012; 319(1):56-65. doi: 10.1016/j.canlet.2011. 12.027 PMID: 22200613; PubMed Central PMCID: PMC3304016.
63. Bouker KB, Skaar TC, Riggins RB, Harburger DS, Fernandez DR, Zwart A, et al. Interferon regulatory factor-1 (IRF-1) exhibits tumor suppressor activities in breast cancer associated with caspase activation and induction of apoptosis. Carcinogenesis. 2005; 26(9):1527-35. doi: 10.1093/carcin/bgi113 PMID: 15878912.
64. Narayan V, Eckert M, Zylicz A, Zylicz M, Ball KL. Cooperative regulation of the interferon regulatory factor-1 tumor suppressor protein by core components of the molecular chaperone machinery. The Journal of biological chemistry. 2009; 284(38):25889-99. doi: 10.1074/jbc.M109.019505 PMID: 19502235; PubMed Central PMCID: PMC2757990.
65. Yanai H, Negishi H, Taniguchi T. The IRF family of transcription factors: Inception, impact and implications in oncogenesis. Oncoimmunology. 2012; 1(8):1376-86. doi: 10.4161/onci.22475 PMID: 23243601; PubMed Central PMCID: PMC3518510.
66. Bowie ML, Ibarra C, Seewalt VL. IRF-1 promotes apoptosis in p53-damaged basal-type human mammary epithelial cells: A model for early basal-type mammary carcinogenesis. Advances in experimental medicine and biology. 2008; 617:367-74. doi: 10.1007/978-0-387-69080-3-35 PMID: 18497060.
67. Bouker KB, Skaar TC, Fernandez DR, O'Brien KA, Riggins RB, Cao D, et al. interferon regulatory factor-1 mediates the proapoptotic but not cell cycle arrest effects of the steroidal antiestrogen ICI 182,780 (faslodex, fulvestrant). Cancer research. 2004; 64(11):4030-9. doi: 10.1158/0008-5472. CAN-03-3602 PMID: 15173018.
68. Kim PK, Armstrong M, Liu Y, Yan P, Bucher B, Zuckerbraun BS, et al. IRF-1 expression induces apoptosis and inhibits tumor growth in mouse mammary cancer cells in vitro and in vivo. Oncogene. 2004; 23(5):1125-35. doi: 10.1038/sj.onc.1207023 PMID: 14762441.
69. Czabotar PE, Lessene G, Strasser A, Adams JM. Control of apoptosis by the BCL-2 protein family: Implications for physiology and therapy. Nature reviews Molecular cell biology. 2014; 15(1):49-63. doi: 10.1038/nrm3722 PMID: 24355989.
70. Parrish AB, Freel CD, Kornbluth S. Cellular mechanisms controlling caspase activation and function. Cold Spring Harbor perspectives in biology. 2013; 5(6). doi: 10.1101/cshperspect.a008672 PMID: 23732469; PubMed Central PMCID: PMC3660825.
71. Silke J, Meier P. Inhibitor of apoptosis (IAP) proteins-modulators of cell death and inflammation. Cold Spring Harbor perspectives in biology. 2013; 5(2). doi: 10.1101/cshperspect.a008730 PMID: 23378585; PubMed Central PMCID: PMC3552501.
72. Vogler M. BCL2A1: The underdog in the BCL2 family. Cell death and differentiation. 2012; 19(1):67-74 doi: 10.1038/cdd.2011.158 PMID: 22075983; PubMed Central PMCID: PMC3252829.
73. Harvat BL, Seth P, Jetten AM. The role of p27Kip1 in gamma interferon-mediated growth arrest of mammary epithelial cells and related defects in mammary carcinoma cells. Oncogene. 1997; 14 (17):2111-22. doi: 10.1038/sj.onc.1201055 PMID: 9160891.
74. Schneider WM, Chevillotte MD, Rice CM. Interferon-stimulated genes: A complex web of host defenses. Annual review of immunology. 2014; 32:513-45. doi: 10.1146/annurev-immunol-032713-120231 PMID: 24555472.
75. Zhang JY, Tao S, Kimmel R, Khavari PA. CDK4 regulation by TNFR1 and JNK is required for NF-kappaB-mediated epidermal growth control. The Journal of cell biology. 2005; 168(4):561-6. doi: 10. 1083/jcb.200411060 PMID: 15699216; PubMed Central PMCID: PMC2171750.
76. Biswas DK, Dai SC, Cruz A, Weiser B, Graner E, Pardee AB. The nuclear factor kappa B (NF-kappa B): A potential therapeutic target for estrogen receptor negative breast cancers. Proceedings of the National Academy of Sciences of the United States of America. 2001; 98(18):10386-91. doi: 10.1073/pnas.151257998 PMID: 11517301; PubMed Central PMCID: PMC56970.
77. Biswas DK, Singh S, Shi Q, Pardee AB, Iglehart JD. Crossroads of estrogen receptor and NF-kappaB signaling. Science's STKE: Signal transduction knowledge environment. 2005; 2005(288):pe27. doi: 10.1126/stke.2882005pe27 PMID: 15956359.
78. Hutti JE, Shen RR, Abbott DW, Zhou AY, Sprott KM, Asara JM, et al. Phosphorylation of the tumor suppressor CYLD by the breast cancer oncogene IKKepsilon promotes cell transformation. Molecular cell. 2009; 34(4):461-72. doi: 10.1016/j.molcel.2009.04.031 PMID: 19481526; PubMed Central PMCID: PMC2746958.
79. Bash J, Zong WX, Gelinas C. c-Rel arrests the proliferation of HeLa cells and affects critical regulators of the G1/S-phase transition. Molecular and cellular biology. 1997; 17(11):6526-36. PMID: 9343416; PubMed Central PMCID: PMC232506.
80. Chapman RS, Duff EK, Lourenco PC, Tonner E, Flint DJ, Clarke AR, et al. A novel role for IRF-1 as a suppressor of apoptosis. Oncogene. 2000; 19(54):6386-91. doi: 10.1038/sj.onc.1204016 PMID: 11175354.
81. Zhu Y, Singh B, Hewitt S, Liu A, Gomez B, Wang A, et al. Expression patterns among interferon regulatory factor-1, human X-box binding protein-1, nuclear factor kappa B, nucleophosmin, estrogen receptor-alpha and progesterone receptor proteins in breast cancer tissue microarrays. International journal of oncology. 2006; 28(1):67-76. PMID: 16327981.
82. Yim JH, Ro SH, Lowney JK, Wu SJ, Connett J, Doherty GM. The role of interferon regulatory factor-1 and interferon regulatory factor-2 in IFN-gamma growth inhibition of human breast carcinoma cell lines. Journal of interferon & cytokine research: The official journal of the International Society for Interferon and Cytokine Research. 2003; 23(9):501-11. doi: 10.1089/10799900360708623 PMID: 14565859.
83. Haq R, Yokoyama S, Hawryluk EB, Jonsson GB, Frederick DT, McHenry K, et al. BCL2A1 is a lineage-specific antiapoptotic melanoma oncogene that confers resistance to BRAF inhibition. Proceedings of the National Academy of Sciences of the United States of America. 2013; 110(11):4321-6. doi: 10.1073/pnas.1205575110 PMID: 23447565; PubMed Central PMCID: PMC3600451.
84. Schwartz-Roberts JL, Cook KL, Chen C, Shajahan-Haq AN, Axelrod M, Warri A, et al. Interferon regulatory factor-1 signaling regulates the switch between autophagy and apoptosis to determine breast cancer cell fate. Cancer research. 2015; 75(6):1046-55. doi: 10.1158/0008-5472.CAN-14-1851 PMID: 25576084; PubMed Central PMCID: PMC4359953.
85. Harada H, Kitagawa M, Tanaka N, Yamamoto H, Harada K, Ishihara M, et al. Anti-oncogenic and oncogenic potentials of interferon regulatory factors-1 and-2. Science. 1993; 259(5097):971-4. PMID: 8438157.
86. Doherty GM, Boucher L, Sorenson K, Lowney J. Interferon regulatory factor expression in human breast cancer. Annals of surgery. 2001; 233(5):623-9. PMID: 11323500; PubMed Central PMCID: PMC1421301.
87. Drew PD, Franzoso G, Carlson LM, Biddison WE, Siebenlist U, Ozato K. Interferon regulatory factor-2 physically interacts with NF-kappa B in vitro and inhibits NF-kappa B induction of major histocompatibility class I and beta 2-microglobulin gene expression in transfected human neuroblastoma cells. Journal of neuroimmunology. 1995; 63(2):157-62. PMID: 8550813.
88. Saccani S, Marazzi I, Beg AA, Natoli G. Degradation of promoter-bound p65/RelA is essential for the prompt termination of the nuclear factor kappaB response. The Journal of experimental medicine. 2004; 200(1):107-13. doi: 10.1084/jem.20040196 PMID: 15226358; PubMed Central PMCID: PMC2213320.
89. Lee TI, Young RA. Transcriptional regulation and its misregulation in disease. Cell. 2013; 152 (6):1237-51. doi: 10.1016/j.cell.2013.02.014 PMID: 23498934; PubMed Central PMCID: PMC3640494.
90. Rozenblatt-Rosen O, Deo RC, Padi M, Adelmant G, Calderwood MA, Rolland T, et al. Interpreting cancer genomes using systematic host network perturbations by tumour virus proteins. Nature. 2012; 487(7408):491-5. doi: 10.1038/nature11288 PMID: 22810586; PubMed Central PMCID: PMC3408847.
91. Finn RS, Dering J, Conklin D, Kalous O, Cohen DJ, Desai AJ, et al. PD 0332991, a selective cyclin D kinase 4/6 inhibitor, preferentially inhibits proliferation of luminal estrogen receptor-positive human breast cancer cell lines in vitro. Breast cancer research: BCR. 2009; 11(5):R77. doi: 10.1186/bcr2419 PMID: 19874578; PubMed Central PMCID: PMC2790859.
92. Comstock CE, Augello MA, Goodwin JF, de Leeuw R, Schiewer MJ, Ostrander WF Jr, et al. Targeting cell cycle and hormone receptor pathways in cancer. Oncogene. 2013; 32(48):5481-91. doi: 10.1038/onc.2013.83 PMID: 23708653; PubMed Central PMCID: PMC3898261.
93. Ning Y, Riggins RB, Mulla JE, Chung H, Zwart A, Clarke R. IFNgamma restores breast cancer sensitivity to fulvestrant by regulating STAT1, IFN regulatory factor 1, NF-kappaB, BCL2 family members, and signaling to caspase-dependent apoptosis. Molecular cancer therapeutics. 2010; 9(5):1274-85. doi: 10.1158/1535-7163.MCT-09-1169 PMID: 20457620; PubMed Central PMCID: PMC2925293.
94. Cerami E, Gao J, Dogrusoz U, Gross BE, Sumer SO, Aksoy BA, et al. The cBio cancer genomics portal: An open platform for exploring multidimensional cancer genomics data. Cancer discovery. 2012; 2 (5):401-4. doi: 10.1158/2159-8290.CD-12-0095 PMID: 22588877; PubMed Central PMCID: PMC3956037.
95. Gao J, Aksoy BA, Dogrusoz U, Dresdner G, Gross B, Sumer SO, et al. Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal. Science signaling. 2013; 6(269):pl1. doi: 10.1126/scisignal.2004088 PMID: 23550210; PubMed Central PMCID: PMC4160307.
96. Hinz M, Arslan SC, Scheidereit C. It takes two to tango: IkappaBs, the multifunctional partners of NFkappaB. Immunological reviews. 2012; 246(1):59-76. doi: 10.1111/j.1600-065X.2012.01102.x PMID: 22435547.
97. Barbie TU, Alexe G, Aref AR, Li S, Zhu Z, Zhang X, et al. Targeting an IKBKE cytokine network impairs triple-negative breast cancer growth. The Journal of clinical investigation. 2014; 124(12):5411-23. doi: 10.1172/JCI75661 PMID: 25365225.
98. Shen RR, Hahn WC. Emerging roles for the non-canonical IKKs in cancer. Oncogene. 2011; 30 (6):631-41. doi: 10.1038/onc.2010.493 PMID: 21042276; PubMed Central PMCID: PMC3235643.
99. Bioinformatics website. Available: Http://bioinformatics.psb.ugent.be/software/details/Venn-Diagrams.
100. Loots GG, Ovcharenko I. rVISTA 2.0: Evolutionary analysis of transcription factor binding sites. Nucleic acids research. 2004; 32(Web Server issue):W217-21. doi: 10.1093/nar/gkh383 PMID: 15215384; PubMed Central PMCID: PMC441521.